Shanghai C&D Innostic Medical Technology Group301584.SZValuation Analysis

As of Oct 19, 2026, Shanghai C&D Innostic Medical Technology Group (301584.SZ) trades at a P/E of 26.60x, P/B of 3.45x, P/S of 0.37x, and a dividend yield of 1.13%.
Longitudinal percentile comparison: P/E sits at the 3rd percentile over the trailing 10Y window (vs. 3rd percentile over 3Y); P/B sits at the 3rd percentile over the trailing 10Y window (vs. 3rd percentile over 3Y); P/S sits at the 3rd percentile over the trailing 10Y window (vs. 3rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 35th percentile within its industry and the 37th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.13%, ranking at the 100th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 0.0 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shanghai C&D Innostic Medical Technology Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.